COMMUNIQUÉS West-GlobeNewswire

HealthEx to Help Americans Bring Their Medical Records into AskMD by Sharecare
27/07/2026
Partnership between Sharecare and HealthEx to support personalized and holistic healthcare navigation in AskMD WASHINGTON, July 27, 2026 (GLOBE NEWSWIRE) -- CMS Health Technology Ecosystem Event – July 27, 2026 – [...]
Vadma Institute Expands Global Practitioner Certification Program as Interest Grows in Its Neuro-Somatic Wellness Method
27/07/2026
Global certification expansion and preliminary HRV-based observational research mark new milestones for the Vadma neuro somatic method Kevin Libawski performs the Vadma neuro-somatic method on clients. LOS ANGELES, July [...]
Parexel Recognized as a World’s Top Disability Inclusive Business by the Disability Index® from Disability:IN
27/07/2026
Reflecting company’s commitment to advancing inclusion and accessibility across its global workforce and in its clinical trials RALEIGH, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical [...]
Cato Healthcare Supply Appoints Ryan F. Zackon as President and Chief Executive Officer
27/07/2026
Experienced Supply Chain Leader Strengthens Executive Leadership Team to Accelerate Growth, Innovation, and International Expansion DALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- Cato Healthcare Supply, a leading healthcare [...]
Flourish Health Raises $46M to Scale Intensive Mental Health Care for Youth in Crisis
27/07/2026
Funding fuels national expansion of model that delivers proven outcomes for high-acuity kids through psychiatrist-led Care Pods and an AI-enabled care delivery platform RICHMOND, Va., July 27, 2026 (GLOBE NEWSWIRE) -- [...]
Cristcot Presents Poster and Select Oral Presentation for Implementing Endocrine Principles to Assess Safety and Compliance within a Clinical Trial at ENDO 2026
27/07/2026
-- Study findings create a framework of protocols for implementing endocrine principles to assess compliance within a clinical trial that can be deployed across medical specialties -- -- Building in hypothalamic- [...]
Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update
27/07/2026
Kennewick, WA, July 27, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ , is pleased to share this update on the meaningful advancements the [...]
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
27/07/2026
The offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral [...]
Micron Biomedical Secures $4.5 Million Federal Contract to Develop First Dissolvable Microarray Radiation/Nuclear Medical Countermeasure
27/07/2026
Next generation approach strengthens national preparedness against nuclear threats by accelerating access to time-sensitive treatments that allow for longer shelf life, simplified distribution and self-administration [...]
Glass House Brands Retains Former DEA Compliance Executive to Advise on Interstate Commerce and Export Opportunities
27/07/2026
LONG BEACH, Calif. and TORONTO, July 27, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (NYSE: GLAS) today announced that the Company has retained Matt Murphy, as [...]
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
27/07/2026
MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet [...]
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
27/07/2026
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
27/07/2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026 NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease [...]
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
27/07/2026
BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that [...]
Picard Medical Receives NYSE American Acceptance of Compliance Plan
27/07/2026
-Company continues advancing long-term growth strategy under accepted compliance plan- TUCSON, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), [...]
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
27/07/2026
VXA-222 advances into next phase at VERAXA ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, today announced the [...]
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
27/07/2026
Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026 WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical- [...]
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
27/07/2026
Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through second closing of [...]
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
27/07/2026
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with [...]

Pages